Citations (108)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
Christoph U Correll, Rakesh Jain, Jonathan M Meyer, Antonia Periclou, Timothy Carrothers, Ágota Barabássy, Mehul Patel & Willie Earley. (2019) Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatric Disease and Treatment 15, pages 2537-2550.
Read now
Read now
Leslie Citrome. (2018) Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatric Disease and Treatment 14, pages 2563-2577.
Read now
Read now
L. Orsolini, C. Tomasetti, A. Valchera, R. Vecchiotti, I. Matarazzo, F. Vellante, F. Iasevoli, E. F. Buonaguro, M. Fornaro, A. L. C. Fiengo, G. Martinotti, M. Mazza, G. Perna, A. Carano, A. De Bartolomeis, M. Di Giannantonio & D. De Berardis. (2016) An update of safety of clinically used atypical antipsychotics. Expert Opinion on Drug Safety 15:10, pages 1329-1347.
Read now
Read now
Lillian Jan Findlay, Peggy El-Mallakh & Rif S El-Mallakh. (2015) Management of bipolar I depression: clinical utility of lurasidone. Therapeutics and Clinical Risk Management 11, pages 75-81.
Read now
Read now
Rachel Franklin, Sam Zorowitz, Andrew K Corse, Alik S Widge & Thilo Deckersbach. (2015) Lurasidone for the treatment of bipolar depression: an evidence-based review. Neuropsychiatric Disease and Treatment 11, pages 2143-2152.
Read now
Read now
Dawn Bruijnzeel, Mehdi Yazdanpanah, Uma Suryadevara & Rajiv Tandon. (2015) Lurasidone in the treatment of schizophrenia: a critical evaluation. Expert Opinion on Pharmacotherapy 16:10, pages 1559-1565.
Read now
Read now
Mauro Giovanni Carta, Maria Francesca Moro, Antonio E Nardi & Joseph R Calabrese. (2015) Potential use of lurasidone for the treatment of bipolar psychosis. Expert Opinion on Investigational Drugs 24:4, pages 575-584.
Read now
Read now
Cecilio Álamo, Francisco López-Muñoz & Pilar García-García. (2014) The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder. Expert Review of Neurotherapeutics 14:6, pages 593-605.
Read now
Read now
Young Sup Woo, Hee Ryung Wang & Won-Myong Bahk. (2013) Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatric Disease and Treatment 9, pages 1521-1529.
Read now
Read now
Frank I Tarazi & Marco A Riva. (2013) The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia. Expert Opinion on Drug Discovery 8:10, pages 1297-1307.
Read now
Read now
William V Bobo. (2013) Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Review of Clinical Pharmacology 6:1, pages 61-91.
Read now
Read now
Silvio Caccia, Luca Pasina & Alessandro Nobili. (2012) Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatric Disease and Treatment 8, pages 155-168.
Read now
Read now
Frank I Tarazi & Stephen M Stahl. (2012) Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opinion on Pharmacotherapy 13:13, pages 1911-1922.
Read now
Read now
Norio Yasui-Furukori. (2012) Update on the development of lurasidone as a treatment for patients with acute schizophrenia. Drug Design, Development and Therapy 6, pages 107-115.
Read now
Read now
Joshua T Kantrowitz & Leslie Citrome. (2012) Lurasidone for schizophrenia: what’s different?. Expert Review of Neurotherapeutics 12:3, pages 265-273.
Read now
Read now
Jose de Leon, Vincenza Santoro, Concetta D'Arrigo & Edoardo Spina. (2012) Interactions between antiepileptics and second-generation antipsychotics. Expert Opinion on Drug Metabolism & Toxicology 8:3, pages 311-334.
Read now
Read now
Ludovic Samalin, Marion Garnier & Pierre-Michel Llorca. (2011) Clinical potential of lurasidone in the management of schizophrenia. Therapeutics and Clinical Risk Management 7, pages 239-250.
Read now
Read now
Kyeong-Ryoon Lee, Yoon-Jee Chae & Tae-Sung Koo. (2011) Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. Xenobiotica 41:12, pages 1100-1107.
Read now
Read now
Philip Gerretsen & Bruce G Pollock. (2011) Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opinion on Drug Safety 10:5, pages 751-765.
Read now
Read now
Silvio Caccia. (2011) Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opinion on Drug Metabolism & Toxicology 7:7, pages 829-846.
Read now
Read now
Leslie Citrome. (2010) Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opinion on Drug Metabolism & Toxicology 6:12, pages 1551-1564.
Read now
Read now
Articles from other publishers (87)
Przemysław J. Danek & Władysława A. Daniel. (2023) The Novel Atypical Antipsychotic Lurasidone Affects Cytochrome P450 Expression in the Liver and Peripheral Blood Lymphocytes. International Journal of Molecular Sciences 24:23, pages 16796.
Crossref
Crossref
Yu-Mei Wei, Xi-Jin Wang, Xiao-Dong Yang, Chuan-Sheng Wang, Li-Li Wang, Xiao-Ying Xu, Gui-Jun Zhao, Bin Li, Dao-Min Zhu, Qi Wu & Yi-Feng Shen. (2023) Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance. World Journal of Psychiatry 13:11, pages 937-948.
Crossref
Crossref
Shohei Okura, Yasuhiko Deguchi, Tetsuji Cho, Yuki Kageyama & Koki Inoue. (2023) Significant Weight Gain With the Administration of Lurasidone and Valproic Acid in Schizophrenia and Bipolar Disorder Patients. Cureus.
Crossref
Crossref
Madhura Rajadhyaksha & Vaishali Londhe. (2023) Bioanalytical liquid chromatography–tandem mass spectrometry method development and validation for quantification of lurasidone in rat plasma using ion pairing agent. Biomedical Chromatography.
Crossref
Crossref
Valerio Ricci, Gabriele Di Salvo & Giuseppe Maina. (2023) Lurasidone in first-episode psychosis with predominant depressive symptoms: a case report. International Clinical Psychopharmacology 38:4, pages 275-280.
Crossref
Crossref
Ashish Patel, Arya Patel, Darshini Patel, Krina Patel & Tushar Bambharoliya. (2023) Mini Review on Cariprazine: A Promising Antipsychotic Agent. CNS & Neurological Disorders - Drug Targets 22:2, pages 226-236.
Crossref
Crossref
Mujeeb U. Shad. (2023) Seventy Years of Antipsychotic Development: A Critical Review. Biomedicines 11:1, pages 130.
Crossref
Crossref
Hiroyuki Uchida, Euitae Kim, L. Fredrik Jarskog, W. Wolfgang Fleischhacker, Gary Remington & Jeffrey A. Lieberman. 2020. Tasman’s Psychiatry. Tasman’s Psychiatry
1
58
.
Kathy Cheng Wang, Qiaohong Guo, Zijian Kuang, Jianyang Jin, Dan Li, Wenbin Chen, Wenquan Zhu & Min Li. (2022) Structural elucidation of two novel degradants of lurasidone and their formation mechanisms under free radical‐mediated oxidative and photolytic conditions via liquid chromatography‐photodiode array/ultraviolet‐tandem mass spectrometry and one‐dimensional/two‐dimensional nuclear magnetic resonance spectroscopy. Journal of Mass Spectrometry 57:7.
Crossref
Crossref
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
1
224
.
Joana F.C. Silva, Mário T.S. Rosado & M. Ermelinda S. Eusébio. (2021) Structure and energetics of intermolecular association in two lurasidone co-amorphous drug systems. Journal of Molecular Structure 1242, pages 130709.
Crossref
Crossref
Tahlia R. Meola, Paul Joyce, Anthony Wignall, Kristen E. Bremmell & Clive A. Prestidge. (2021) Harnessing the potential of nanostructured formulations to mimic the food effect of lurasidone. International Journal of Pharmaceutics 608, pages 121098.
Crossref
Crossref
Jonathan M. Meyer & Stephen M. Stahl. 2021. The Clinical Use of Antipsychotic Plasma Levels. The Clinical Use of Antipsychotic Plasma Levels
337
371
.
Jonathan M. Meyer & Stephen M. Stahl. 2021. The Clinical Use of Antipsychotic Plasma Levels. The Clinical Use of Antipsychotic Plasma Levels
13
33
.
Jonathan M. Meyer & Stephen M. Stahl. 2021. The Clinical Use of Antipsychotic Plasma Levels. The Clinical Use of Antipsychotic Plasma Levels
xiii
xx
.
Mayank Gupta & Gary Hoover. (2020) Lurasidone an Effective Alternative for the Treatment of Irritability Associated With Autism Spectrum Disorder. Cureus.
Crossref
Crossref
Vishwas P. Pardhi & Swaran Flora. (2020) Stable solid dispersion of lurasidone hydrochloride with augmented physicochemical properties for the treatment of schizophrenia and bipolar disorder. Biopharmaceutics & Drug Disposition 41:8-9, pages 334-351.
Crossref
Crossref
Marcin Siwek, Anna J. Krupa & Anna Wasik. (2020) Lurasidone – pharmacodynamic and pharmacokinetic properties, clinical potential and interaction risk. Pharmacotherapy in Psychiatry and Neurology 36:2, pages 117-134.
Crossref
Crossref
Harshita Gupta, Rutu Panchal, Niyati Acharya & Priti Jignesh Mehta. (2020) Controlled Parenteral Formulations: An Efficacious and Favourable Way to Deliver the Anti-psychotic Drugs. Current Psychiatry Research and Reviews 16:1, pages 42-59.
Crossref
Crossref
Weili Heng, Meiling Su, Hao Cheng, Peiya Shen, Shujun Liang, Linghe Zhang, Yuanfeng Wei, Yuan Gao, Jianjun Zhang & Shuai Qian. (2019) Incorporation of Complexation into a Coamorphous System Dramatically Enhances Dissolution and Eliminates Gelation of Amorphous Lurasidone Hydrochloride. Molecular Pharmaceutics 17:1, pages 84-97.
Crossref
Crossref
Mehmet Emin Demirkol, Lut Tamam, Soner Çakmak & Caner Yeşiloğlu. (2019) Antipsikotik İlaç Kullanımının Elektrokardiyografi Parametreleri ile İlişkisi-. Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry 11, pages 136-146.
Crossref
Crossref
M. S. Sudhir, R. Venkata Nadh & H. Manjunatha. (2019) Oxidative Coupling Reaction for the Determination of Lurasidone. Journal of Analytical Chemistry 74:6, pages 528-533.
Crossref
Crossref
Aishwarya K. Rajagopalan, William K. Bache, Serena Z. Chen, Ermal Bojdani & Kevin J. Li. (2019) New-generation Antipsychotics and Cardiovascular Risk. Current Treatment Options in Psychiatry 6:2, pages 154-163.
Crossref
Crossref
Lily Xu & Saroja Krishnaswamy. (2018) Switch-associated adverse events: focus on olanzapine. Australasian Psychiatry 26:6, pages 635-639.
Crossref
Crossref
Balaswamy Reddy, Soumitra Das & Mustafa Ali. (2018) A Case of Hypersexuality Probably Associated With Lurasidone. Journal of Clinical Psychopharmacology 38:5, pages 537-539.
Crossref
Crossref
Jiang Li, Antony Loebel & Herbert Y. Meltzer. (2018) Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials. Schizophrenia Research 199, pages 203-213.
Crossref
Crossref
Tomasz Klucznik, Barbara Mikulak-Klucznik, Michael P. McCormack, Heather Lima, Sara Szymkuć, Manishabrata Bhowmick, Karol Molga, Yubai Zhou, Lindsey Rickershauser, Ewa P. Gajewska, Alexei Toutchkine, Piotr Dittwald, Michał P. Startek, Gregory J. Kirkovits, Rafał Roszak, Ariel Adamski, Bianka Sieredzińska, Milan Mrksich, Sarah L.J. Trice & Bartosz A. Grzybowski. (2018) Efficient Syntheses of Diverse, Medicinally Relevant Targets Planned by Computer and Executed in the Laboratory. Chem 4:3, pages 522-532.
Crossref
Crossref
Penelope Lowe, Amir Krivoy, Lilla Porffy, Erna Henriksdottir, Whiskey Eromona & Sukhwinder S. Shergill. (2017) When the drugs don’t work: treatment-resistant schizophrenia, serotonin and serendipity. Therapeutic Advances in Psychopharmacology 8:1, pages 63-70.
Crossref
Crossref
Marta Kot, Anna Haduch, Mariusz Papp & Władysława A. Daniel. (2017) The Effect of Chronic Treatment with Lurasidone on Rat Liver Cytochrome P450 Expression and Activity in the Chronic Mild Stress Model of Depression. Drug Metabolism and Disposition 45:12, pages 1336-1344.
Crossref
Crossref
Emad B. Basalious & M. Abdallah Ahmed. (2017) Phospholipid based self-nanoemulsifying self-nanosuspension (p-SNESNS) as a dual solubilization approach for development of formulation with diminished food effect: Fast/fed in vivo pharmacokinetics study in human. European Journal of Pharmaceutical Sciences 109, pages 244-252.
Crossref
Crossref
Chaoying Hu, Yijun Wang, Rong Song, Chen Yu, Xiaoyan Luo & Jingying Jia. (2017) Single- and Multiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects. Clinical Drug Investigation 37:9, pages 861-871.
Crossref
Crossref
Alfredo Meneses. (2017) Frameworking memory and serotonergic markers. Reviews in the Neurosciences 28:5, pages 455-497.
Crossref
Crossref
A H Ashok, T R Marques, S Jauhar, M M Nour, G M Goodwin, A H Young & O D Howes. (2017) The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Molecular Psychiatry 22:5, pages 666-679.
Crossref
Crossref
William M. Greenberg & Leslie Citrome. (2016) Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature. Clinical Pharmacokinetics 56:5, pages 493-503.
Crossref
Crossref
Nicolas A. Nuñez & Gabriella Gobbi. (2017) Lurasidone and Mood Stabilizers in Treatment-Resistant Unipolar Depression. Journal of Clinical Psychopharmacology 37:2, pages 263-264.
Crossref
Crossref
Michele Fornaro, Domenico De Berardis, Giampaolo Perna, Marco Solmi, Nicola Veronese, Laura Orsolini, Elisabetta Filomena Buonaguro, Felice Iasevoli, Cristiano André Köhler, André Ferrer Carvalho & Andrea de Bartolomeis. (2017) Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. BioMed Research International 2017, pages 1-17.
Crossref
Crossref
Wojciech Datka, Rafal R Jaeschke, Krzysztof Styczeñ, Magdalena Koperny, Marcin Waligora, Joanna Hubert & Dawid Storman. (2016) Lurasidone versus typical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Rafał R. Jaeschke, Magdalena Sowa-Kućma, Patrycja Pańczyszyn-Trzewik, Paulina Misztak, Krzysztof Styczeń & Wojciech Datka. (2016) Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile. Pharmacological Reports 68:4, pages 748-755.
Crossref
Crossref
Mahitej Yadav Katteboina, Nageswara Rao Pilli, Ramesh Mullangi, Raghunadha Reddy Seelam & Shobha Rani Satla. (2016) LC-MS/MS assay for the determination of lurasidone and its active metabolite, ID-14283 in human plasma and its application to a clinical pharmacokinetic study. Biomedical Chromatography 30:7, pages 1065-1074.
Crossref
Crossref
Masakuni Horiguchi, Masanori Miyauchi, Nichole M. Neugebauer, Yoshihiro Oyamada & Herbert Y. Meltzer. (2016) Prolonged reversal of the phencyclidine-induced impairment in novel object recognition by a serotonin (5-HT)1A-dependent mechanism. Behavioural Brain Research 301, pages 132-141.
Crossref
Crossref
W. Wolfgang Fleischhacker & Seiya Miyamoto. (2016) Pharmacological Treatment of Schizophrenia:. Clinical Neuropsychopharmacology and Therapeutics 7:0, pages 1-8.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
87
110
.
Robert L. Findling, Robert Goldman, Yu-Yuan Chiu, Robert Silva, Fengbin Jin, Andrei Pikalov & Antony Loebel. (2015) Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With Psychiatric Disorders. Clinical Therapeutics 37:12, pages 2788-2797.
Crossref
Crossref
Yiding Chen & Michael C. Willis. (2015) An Aryne-Based Route to Substituted Benzoisothiazoles. Organic Letters 17:19, pages 4786-4789.
Crossref
Crossref
Seiya Miyamoto, David B. Merrill, L. Fredrik Jarskog, W. Wolfgang Fleishhacker, Stephen R. Marder & Jeffrey A. Lieberman. 2015. Psychiatry. Psychiatry
2088
2128
.
Konstantinos N. Fountoulakis, Maria Gazouli, John Kelsoe & Hagop Akiskal. (2015) The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder. European Neuropsychopharmacology 25:3, pages 335-342.
Crossref
Crossref
M.V.N. Kumar Talluri, Shireesha Dharavath, Pradipbhai D. Kalariya, B. Prasanth & R. Srinivas. (2015) Structural characterization of alkaline and oxidative stressed degradation products of lurasidone using LC/ESI/QTOF/MS/MS. Journal of Pharmaceutical and Biomedical Analysis 105, pages 1-9.
Crossref
Crossref
Gabor P. Molnar, Laura C. Grimsich, Glenn Catalano & Maria C. Catalano. (2014) Acute Lurasidone Overdose. Journal of Clinical Psychopharmacology 34:6, pages 768-770.
Crossref
Crossref
Steven G. Potkin, David B. Keator, Marilyn L. Kesler-West, Dana D. Nguyen, Theo. G. M. van Erp, Jogeshwar Mukherjee, Nikunj Shah & Adrian Preda. (2013)
D
2
receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder
. CNS Spectrums 19:2, pages 176-181.
Crossref
Crossref
Dean F. Wong, Hiroto Kuwabara, James Robert Brašić, Thomas Stock, Atul Maini, Emily G. Gean & Antony Loebel. (2013) Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology 229:2, pages 245-252.
Crossref
Crossref
Sheldon Preskorn, Larry Ereshefsky, Yu‐Yuan Chiu, Nagaraju Poola & Antony Loebel. (2013) Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open‐label, crossover studies. Human Psychopharmacology: Clinical and Experimental 28:5, pages 495-505.
Crossref
Crossref
Melvin George, Radhika Amrutheshwar, Ravi Philip Rajkumar, Shivanand Kattimani & Steven Aibor Dkhar. (2013) Newer antipsychotics and upcoming molecules for schizophrenia. European Journal of Clinical Pharmacology 69:8, pages 1497-1509.
Crossref
Crossref
Lindsay N. Cates, Amanda J. Roberts, Salvador Huitron-Resendiz & Peter B. Hedlund. (2013) Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype. Neuropharmacology 70, pages 211-217.
Crossref
Crossref
Anja Cerovecki, Richard Musil, Ansgar Klimke, Florian Seemüller, Ekkehard Haen, Rebecca Schennach, Kai-Uwe Kühn, Hans-Peter Volz & Michael Riedel. (2013) Withdrawal Symptoms and Rebound Syndromes Associated with Switching and Discontinuing Atypical Antipsychotics: Theoretical Background and Practical Recommendations. CNS Drugs 27:7, pages 545-572.
Crossref
Crossref
F. Calabrese, A. Luoni, G. Guidotti, G. Racagni, F. Fumagalli & M. A. Riva. (2012) Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid. Psychopharmacology 226:1, pages 101-112.
Crossref
Crossref
David N. Osser, Mohsen Jalali Roudsari & Theo Manschreck. (2013) The Psychopharmacology Algorithm Project at the Harvard South Shore Program. Harvard Review of Psychiatry 21:1, pages 18-40.
Crossref
Crossref
Shunsuke Nakazawa, Chihiro Yokoyama, Naohiro Nishimura, Tomoko Horisawa, Akihiro Kawasaki, Hiroshi Mizuma, Hisashi Doi & Hirotaka Onoe. (2012) Evaluation of dopamine D2/D3 and serotonin 5-HT2A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography. Psychopharmacology 225:2, pages 329-339.
Crossref
Crossref
Lisbeth Patteet, Manuel Morrens, Kristof E. Maudens, Peter Niemegeers, Bernard Sabbe & Hugo Neels. (2012) Therapeutic Drug Monitoring of Common Antipsychotics. Therapeutic Drug Monitoring 34:6, pages 629-651.
Crossref
Crossref
Osamu Ichikawa, Kazuhiko Okazaki, Hiroyuki Nakahira, Megumi Maruyama, Ryu Nagata, Kumiko Tokuda, Tomoko Horisawa & Kazuto Yamazaki. (2012) Structural insight into receptor-selectivity for lurasidone. Neurochemistry International 61:7, pages 1133-1143.
Crossref
Crossref
Nobumi Miyake, Seiya Miyamoto & L. Fredrik Jarskog. (2012) New Serotonin/Dopamine Antagonists for the Treatment of Schizophrenia. Clinical Schizophrenia & Related Psychoses 6:3, pages 122-133.
Crossref
Crossref
Jeffrey Rado & Philip G. Janicak. (2012) Pharmacological and Clinical Profile of Recently Approved Second-Generation Antipsychotics. Drugs & Aging 29:10, pages 783-791.
Crossref
Crossref
Leslie Citrome. (2012) Lurasidone in Schizophrenia: New Information About Dosage and Place in Therapy. Advances in Therapy 29:10, pages 815-825.
Crossref
Crossref
Yoon-Jee Chae, Tae-Sung Koo & Kyeong-Ryoon Lee. (2012) A Sensitive and Selective LC-MS Method for the Determination of Lurasidone in Rat Plasma, Bile, and Urine. Chromatographia 75:19-20, pages 1117-1128.
Crossref
Crossref
Nga Tran & Deirdre Alderton. 2012. Pharmacological and Psychosocial Treatments in Schizophrenia, Third Edition. Pharmacological and Psychosocial Treatments in Schizophrenia, Third Edition
1
31
.
Masakuni Horiguchi, Kayleen E Hannaway, Adesewa E Adelekun, Karu Jayathilake & Herbert Y Meltzer. (2012) Prevention of the Phencyclidine-Induced Impairment in Novel Object Recognition in Female Rats by Co-Administration of Lurasidone or Tandospirone, a 5-HT1A Partial Agonist. Neuropsychopharmacology 37:10, pages 2175-2183.
Crossref
Crossref
Philip G. Janicak & Jeffrey Rado. (2012) Recent Second-Generation Antipsychotics. Psychopharm Review 47:8, pages 57-64.
Crossref
Crossref
Brett A. English, Marcus Dortch, Larry Ereshefsky & Stanford Jhee. (2012) Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting. Current Psychiatry Reports 14:4, pages 376-390.
Crossref
Crossref
Vineeta Risbood, Jennifer R Lee, Jennifer Roche-Desilets & Matthew A Fuller. (2012) Lurasidone: An Atypical Antipsychotic for Schizophrenia. Annals of Pharmacotherapy 46:7-8, pages 1033-1046.
Crossref
Crossref
Mei Huang, Masakuni Horiguchi, Anna R. Felix & Herbert Y. Meltzer. (2012) 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. NeuroReport 23:7, pages 436-440.
Crossref
Crossref
David J. Castle, Nga Tran & Deirdre Alderton. 2012. Pharmacological and Psychosocial Treatments in Schizophrenia. Pharmacological and Psychosocial Treatments in Schizophrenia
1
31
.
M. Horiguchi & H. Y. Meltzer. (2012) The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology 221:2, pages 205-215.
Crossref
Crossref
Fabio Fumagalli, Francesca Calabrese, Alessia Luoni, Francesca Bolis, Giorgio Racagni & Marco A. Riva. (2011) Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. The International Journal of Neuropsychopharmacology 15:02, pages 235-246.
Crossref
Crossref
Eunice Y. Yuen, Xiangning Li, Jing Wei, Masakuni Horiguchi, Herbert Y. Meltzer & Zhen Yan. (2012)
The Novel Antipsychotic Drug Lurasidone Enhances
N
-Methyl-d-aspartate Receptor-Mediated Synaptic Responses
. Molecular Pharmacology 81:2, pages 113-119.
Crossref
Crossref
Masakuni Horiguchi, Mei Huang & Herbert Y. Meltzer. (2011) Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology 217:1, pages 13-24.
Crossref
Crossref
David R. P. Guay. (2011) Comment on the Potential Utility of the New Atypical Antipsychotic Lurasidone in the Geriatric Population. The Consultant Pharmacist 26:8, pages 579-582.
Crossref
Crossref
M. Horiguchi, M. Huang & H. Y. Meltzer. (2011) The Role of 5-Hydroxytryptamine 7 Receptors in the Phencyclidine-Induced Novel Object Recognition Deficit in Rats. Journal of Pharmacology and Experimental Therapeutics 338:2, pages 605-614.
Crossref
Crossref
Sarah M. Fayad & Rajiv Tandon. (2011) Lurasidone: The Most Recent Addition to Our Antipsychotic Armamentarium. Psychopharm Review 46:6, pages 41-47.
Crossref
Crossref
Tomoko Horisawa, Tadashi Ishibashi, Hiroyuki Nishikawa, Takeshi Enomoto, Satoko Toma, Takeo Ishiyama & Mutsuo Taiji. (2011) The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: Mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behavioural Brain Research 220:1, pages 83-90.
Crossref
Crossref
Philip D. Harvey, Masaaki Ogasa, Josephine Cucchiaro, Antony Loebel & Richard S.E. Keefe. (2011) Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophrenia Research 127:1-3, pages 188-194.
Crossref
Crossref
Stefan Bräse. (2011) Organische Chemie 2010. Nachrichten aus der Chemie 59:3, pages 254-283.
Crossref
Crossref
L. Citrome. (2011) Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. International Journal of Clinical Practice 65:2, pages 189-210.
Crossref
Crossref
HY Meltzer & BW Massey. (2011) The role of serotonin receptors in the action of atypical antipsychotic drugs. Current Opinion in Pharmacology 11:1, pages 59-67.
Crossref
Crossref
Rif S. El-MallakhAhmed Z. ElmaadawiYonglin GaoKavita LohanoR. Jeannie Roberts. (2011) Current and Emerging Therapies for the Management of Bipolar Disorders. Journal of Central Nervous System Disease 3, pages JCNSD.S4441.
Crossref
Crossref
Leslie Citrome. (2011) Lurasidone for Schizophrenia: A Brief Review of a New Second-Generation Antipsychotic. Clinical Schizophrenia & Related Psychoses 4:4, pages 251-257.
Crossref
Crossref
Joanne Bronson, Murali Dhar, William Ewing & Nils Lonberg. 2011.
433
502
.
Rajiv Tandon, Henry A. Nasrallah & Matcheri S. Keshavan. (2010) Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future. Schizophrenia Research 122:1-3, pages 1-23.
Crossref
Crossref
Gregor J. Macdonald & José Manuel Bartolomé. 2010.
37
80
.